Knoa Pharma: Attention Deficit Disorder with Hyperactivity trials
The registry lists 12 Attention Deficit Disorder with Hyperactivity studies with Knoa Pharma as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 3 7Phase 4 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in ChildrenTerminatedNCT04987762Phase 4Results posted
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)TerminatedNCT04507204Phase 4Results posted
- A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHDCompletedNCT02683265Phase 4Results posted
- Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHDCompletedNCT02470234Phase 4Results posted
- The Efficacy and Safety of PRC-063 in Adult ADHD PatientsCompletedNCT02139124Phase 3Results posted
- Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom SettingCompletedNCT01269463Phase 3Results posted
- Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHDCompletedNCT01239030Phase 3Results posted
- A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHDStatus unknownNCT02677519Phase 4
- A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHDCompletedNCT02555150Phase 3
- PRC-063 in an ADULT Workplace EnvironmentCompletedNCT02225639Phase 3
- Long-Term Safety of PRC-063 in Adolescents and Adults With ADHDCompletedNCT02168127Phase 3
- PRC-063 in Adolescent ADHDCompletedNCT02139111Phase 3